NEW ORLEANS -- Off-label use of oral elagolix (Orilissa) may be a more patient-friendly alternative to standard-of-care injectable GnRH antagonists for ovulation suppression during in vitro ...

- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - ...

Two Sealed Airtight Medical Vials Against Bright Background Front View. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations.

Gonadotropin-releasing hormone (GnRH) therapy improves cognitive function in Down syndrome (DS) mouse models and male patients with DS, according to a new study. The findings reveal a previously ...